Oral and maxillofacial clinical features of Ehlers-Danlos syndrome: a systematic review
Abstract
BACKGROUND
Ehlers-Danlos syndromes (EDS) are inherited connective tissue disorders with diverse clinical manifestations, complicating subtype classification. While joint hypermobility, skin hyperextensibility, and tissue fragility are key diagnostic features, oral and maxillofacial signs are often overlooked.
OBJECTIVE
This review compiles dental and maxillofacial manifestations in EDS patients and identifies subtype-specific features to assist diagnosis.
STUDY DESIGN
This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was registered on PROSPERO (CRD42023410501). Studies published from 1969 to March 2023 were screened. Eligible studies included original articles, case series, and case reports involving human subjects with any EDS subtype reporting dental or maxillofacial features.
RESULTS
Subtype-specific maxillofacial features included nasal bridge depression in 80% of arthrochalasia EDS, downslanting palpebral fissures in 80% of kyphoscoliotic EDS, and deep-set eyes in 34% of classical EDS (cEDS). Oral anomalies comprised tooth agenesis in 50% of spondylodysplastic and 75% of dermatosparactic EDS cases. Dental malformations included pulpal calcifications (11/89 cEDS), root fusion (8/31 vascular EDS [vEDS]), and excessive root length (11/31 vEDS). Gingival hyperplasia was reported in 100% of dermatosparactic EDS cases. The absence of labial and/or lingual frenula remains debated.
CONCLUSIONS
This review…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.